Single Institution Review of Patients With Prior Breast Augmentation Undergoing Breast Conservation Therapy for Breast Cancer.

Ann Plast Surg

From the *H. Lee Moffitt Cancer Center and Research Institute; and †Division of Plastic Surgery, Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, FL.

Published: June 2017

Background: Increasing number of patients with preexisting breast implants desire breast conservation therapy for breast cancer. There is paucity of comparative data on tumor margins and re-excisions in these patients. High re-excision rates up to 25% have been reported in breast conservation therapy patients; efforts to obtain cosmesis and avoid implant rupture might increase this further. We analyzed tumor margins, re-excision rates, and recurrence in previously augmented versus non-augmented patients undergoing lumpectomy for breast cancer. We preserved preexisting implants if feasible with oncologic clearance and cosmesis.

Methods: Institutional review board-approved retrospective analysis was performed on patients undergoing lumpectomy with history of prior breast augmentation (N = 52) and consecutively selected non-augmented patients (N = 51). Based on tumor distance to inked margin, we grouped margins as negative (≥2 mm), close (<2 mm), and positive. Patients were followed up clinically and with imaging in the outpatient clinic, and recurrences were documented.

Results: Patients in the non-augmented group were significantly more likely to have larger tumors (T2 and above; P = 0.05) compared with the augmented group. Although more patients in the augmented group had positive margins, this was not statistically significant (6 vs 3, P = 0.86). No difference was noted between re-excision rates among the augmented versus non-augmented groups (21.1% vs 19.6%, respectively; odds ratio, 0.91; 95% confidence interval, 0.35-2.37; P = 0.85); these remained unchanged even when adjusting for tumor stage (P = .75) and margins (P = 0.73). Although more patients in the augmented group recurred (4 vs 0), this was not statistically significant (P = 0.1).

Conclusions: Our results indicate that, from the oncological standpoint, patients with prior augmentation can undergo lumpectomy with equivalent tumor margins and re-excision rates. To the best of our knowledge, this is the first reported comparative study between these 2 groups.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SAP.0000000000001040DOI Listing

Publication Analysis

Top Keywords

breast conservation
12
conservation therapy
12
breast cancer
12
breast
9
prior breast
8
breast augmentation
8
therapy breast
8
tumor margins
8
re-excision rates
8
non-augmented patients
8

Similar Publications

Breast cancer is the most common cancer type among women according to the World Health Organization data. While breast-conserving surgery has been increasingly performed in patients with early-stage breast cancer, unilateral or bilateral mastectomy is still performed in many patients. With the changes in mastectomy techniques and the development of breast reconstruction techniques over the years, today the aim of breast reconstruction is to create breast tissue in a shape and symmetry that will correct the anatomical defect that occurs after mastectomy, without affecting the patient's oncological treatment.

View Article and Find Full Text PDF

Assessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model.

Phys Med Biol

January 2025

Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.

The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.

View Article and Find Full Text PDF

Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.

Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.

View Article and Find Full Text PDF

Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.

Research (Wash D C)

January 2025

Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming, Yunnan 650201, China.

Immune recognition and activation by the peptide-laden major histocompatibility complex-T cell receptor (TCR)-CD3 complex is essential for anti-tumor immunity. Tumors may escape immune surveillance by dissembling the complex. Here, we report that transferrin, which is overexpressed in patients with liver metastasis, disassociates TCR from the CD3 signaling apparatus by targeting the constant domain (CD) of T cell receptor α (TCRα), consequently suppresses T cell activation, and inhibits anti-metastatic and anti-tumor immunity.

View Article and Find Full Text PDF

Background: Male breast cancer (MBC) is a rare disease, accounting for 1% of all breast cancers diagnosed in the United States. The rarity of MBC has limited the development of treatment algorithms specific to men. Thus, the standard of care has been mastectomy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!